04.08.2017 • Newsanimal healthCorden Pharmadrug products

CordenPharma Expands Manufacturing Capacities for Veterinary Drug Products

CordenPharmas Plankstadt facility. Former AstraZeneca Plankstadt plant acquired...
CordenPharma's Plankstadt facility. Former AstraZeneca Plankstadt plant acquired by ICIG to become CordenPharma Plankstadt GmbH in 2007/08. © CordenPharma International

CordenPharma, a contract manufacturer for APIs, drug products and packaging, announced the design and installment of a new manufacturing line at its Plankstadt, Germany site. The new line is part of a production plant that is dedicated to veterinary drug products, the company said.

According to CordenPharma the expansion of manufacturing capabilities at Plankstadt is the result of a recently signed long-term custom manufacturing agreement for an animal health application. The name of the customer was not disclosed. Work is scheduled to begin in the second half of 2017, with a targeted mechanical completion by Q2 of 2018 and commercial supply for the global launch campaign planned to start in the second half of 2018.

“This is an extremely important and significant investment for CordenPharma Plankstadt. This new production line will allow the fully contained handling of highly potent APIs in a dedicated facility for the manufacturing of Veterinary Drug Products. This is a unique opportunity in the industry,” said Frank Hähner, managing director of CordenPharma Plankstadt.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.